ADU-S100 was evaluated in a phase I clinical trial involving 47 patients with advanced/metastatic solid tumors or lymphomas, either alone or in combination with ipilimumab, an immune checkpoint inhibitor that targets CTLA-4 (NCT02675439). This evidence concerns the gene CTLA4 and lymphoma.